A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)

The EUROLIGHT registry study collects real-world data on the safety and effectiveness of photobiomodulation (PBM) therapy — a non-invasive light-based treatment using the Valeda device — in patients with dry age-related macular degeneration (AMD), a leading cause of vision loss in older adults. Participants receive up to nine short treatment sessions over 3–4 weeks, with optional additional rounds every 4–6 months, while standard vision tests and retinal imaging are collected before and after treatment. Adults with a confirmed diagnosis of dry AMD who can cooperate with study procedures and provide informed consent are eligible; patients with a history of wet (exudative) AMD, diabetic macular edema, or photosensitivity disorders are excluded. Participation combines standard clinical care with registry data collection at participating European centers. This summary was prepared as patient-facing educational content using AI assistance.